2 Result: Immunovant
BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
October 13th, 2023
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the peri. Read more
Immunovant's IMVT-1402 Data Sparks Momentum; Ferguson Outperforms Estimates
September 26th, 2023
Shares of Immunovant, Inc. (Nasdaq: IMVT) surged by more than 40% in pre-market trading after promising Phase 1 trial results for IMVT-1402. Administered subcutaneously in healthy adults, IMVT-1402 demonstrated significant dose-dependent reductions i. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025
Member Login